NLSP - NLS Pharmaceutics Total Debt to Capital

The price trend shown below illustrates the total debt-to-equity dynamics of NLS Pharmaceutics AG (NLSP), which stands at 0.00. The business is scaling through the development of narcolepsy medications, leveraging patent protection to achieve high margins with low production costs. Stable demand for such drugs renders the company a defensive asset. Financial success here depends on regulatory approvals and medical test results rather than macroeconomic factors.

This ratio determines the degree of financial leverage by comparing total liabilities to equity to assess the stability of the capital structure. By analyzing the leverage ratio—total debt to equity—an investor evaluates the bankruptcy risks or expansion potential of NLS Pharmaceutics AG, whose clinical trial outsourcing model minimizes capital expenditures on plants in favor of intellectual property.